Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

Lamberti, María Julia; Nigro, Annunziata; Mentucci, Fátima María; Rumie Vittar, Natalia Belén; Casolaro, Vincenzo; Dal Col, Jessica

doi:10.3390/pharmaceutics12030256

Open AccessReview

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

by

María Julia Lamberti

^1,2

,

Annunziata Nigro

³,

Fátima María Mentucci

^1,2,

Natalia Belén Rumie Vittar

^1,2,*,

Vincenzo Casolaro

³

and

Jessica Dal Col

^3,*

¹

Departamento de Biología Molecular, Universidad Nacional de Río Cuarto, Río Cuarto 5800, Córdoba, Argentina

²

INBIAS, CONICET-UNRC, Río Cuarto 5800, Córdoba, Argentina

³

Department of Medicine, Surgery and Dentistry ‘Scuola Medica Salernitana’, University of Salerno, 84081 Baronissi, Salerno, Italy

^*

Authors to whom correspondence should be addressed.

Pharmaceutics 2020, 12(3), 256; https://doi.org/10.3390/pharmaceutics12030256

Submission received: 28 January 2020 / Revised: 5 March 2020 / Accepted: 10 March 2020 / Published: 12 March 2020

(This article belongs to the Special Issue Dendritic Cell Vaccines)

Download

Browse Figures

Review Reports Versions Notes

Abstract

The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.

Keywords: immunogenic cell death; dendritic cell-based vaccination; immunotherapy; cancer treatment

Graphical Abstract

Share and Cite

MDPI and ACS Style

Lamberti, M.J.; Nigro, A.; Mentucci, F.M.; Rumie Vittar, N.B.; Casolaro, V.; Dal Col, J. Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity. Pharmaceutics 2020, 12, 256. https://doi.org/10.3390/pharmaceutics12030256

AMA Style

Lamberti MJ, Nigro A, Mentucci FM, Rumie Vittar NB, Casolaro V, Dal Col J. Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity. Pharmaceutics. 2020; 12(3):256. https://doi.org/10.3390/pharmaceutics12030256

Chicago/Turabian Style

Lamberti, María Julia, Annunziata Nigro, Fátima María Mentucci, Natalia Belén Rumie Vittar, Vincenzo Casolaro, and Jessica Dal Col. 2020. "Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity" Pharmaceutics 12, no. 3: 256. https://doi.org/10.3390/pharmaceutics12030256

APA Style

Lamberti, M. J., Nigro, A., Mentucci, F. M., Rumie Vittar, N. B., Casolaro, V., & Dal Col, J. (2020). Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity. Pharmaceutics, 12(3), 256. https://doi.org/10.3390/pharmaceutics12030256

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI